Citigroup downgrades King Pharmaceuticals (NYSE: KG) from Hold to Sell. Price target lowered from $21 to $16.

Citigroup ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE